‡Category 2A recommendation is based upon lower-level evidence; there is uniform NCCN® consensus that the intervention is appropriate. All recommendations are Category 2A unless otherwise specified.
NCCN makes no warranties of any kind whatsoever regarding their content, use, or application, and disclaims any responsibility for their application or use in any way. To view the most recent and complete version of the guidelines, go online to NCCN.org.
NCCN is a registered trademark of the National Comprehensive Cancer Network® (NCCN®).
NCCN®=National Comprehensive Cancer Network® (NCCN®).
|Chapter 1||Dr Cohen's introduction and background on CSCC|
|Chapter 2||Overview of LIBTAYO|
|Chapter 3||LIBTAYO clinical trial designs for Study 1423 and Study 1540|
|Chapter 4||Efficacy results of LIBTAYO in advanced CSCC (time to response, objective response rate, duration of response)|
|Chapter 5||Safety profile of LIBTAYO in advanced CSCC|
|Chapter 6||Important Safety Information|
References: 1. LIBTAYO (cemiplimab-rwlc) injection full U.S. prescribing information. Regeneron Pharmaceuticals, Inc., and sanofi-aventis U.S. LLC. 2. Data on file. Regeneron Pharmaceuticals, Inc. 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Squamous Cell Skin Cancer V.1.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed September 27, 2020. To view the most recent and complete version of the guidelines, go online to NCCN.org.